Τόμος 23 (2005) – Τεύχος 3 – Άρθρο 2 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 23 (2005) – Issue 3 – Article 2 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Σοφία Κωστούδη, Χαρίκλεια Κουτούση, Μαρία Μυρωνίδου-Τζουβελέκη

Εργαστήριο Φαρμακολογίας, Ιατρική Σχολή, Αριστοτέλειο Πανεπιστήμιο, Θεσσαλονίκη, Ελλάς

Sofia Kostoudi, Chariklia Koutousi, Maria Mironidou-Tzouveleki

Department of Pharmacology, Medical School, Aristotle University, Thessaloniki, Greece

2. http://www.onlinepot.org/medical/cannabis.htm

3. http://chemweb.calpoly.edu/chem/bailey/377/PapersW 03/ Charity

4. http://www.ukcia.org/research/ForbiddenMedicineChap ter1. html

5. http://www.a1b2c3.com/drugs/mj019.htm

6. http://perso.easynet.fr/baillement/melis-ragiolas/cannabinoid -piomelli.html

7. Λογαράς Γ.: Φαρμακολογία, τ. γ΄, σελ. 129-134, Θεσσαλονίκη, 1971

8. http://www.magnet.gr/drugs/CannabisBook/cannabis8. htm

9. Williamson EM., Evans FJ.: Cannabinoids in clinical prac­tice. Drugs 60: 1303-1314 (2000)

10. Yamamoto T., Takada K.: Role of cannabinoid recep­tor in the brain as it relates to drug reward. Jpn J. Pharma­col. 84: 229-236 (2000)

11. Watts G.: High hopes for cannabinoid analgesia. BMJ 329: 257-278 (2004)

12. Goutopoulos A., Makriyannis A.: From cannabis to can­nabinergics: new therapeutic opportunities. Pharmacol. Ther. 95: 103-117 (2002)

13. Davane W.: New dawn of cannabinoid pharmacology. TiPS 15: 40-41 (1994)

14. Guzman Μ., Galve-Roperh I., Sanchez C.: Ceramide: A new second messenger of cannabinoid action. TiPS 22: 19-22 (2001)

15. Piomelli D., Giuffrida A., Calignano A., de Fonseca F.: The endocannabinooid system as a target for therapeutic drugs. TiPS 21: 218-224 (2000)

16. http://perso.easynet.fr/baillement/melis-ragiolas/cannabino id-beltramo.html

17. Van Oosten B.W., Killestein J., Mathus-Vliegen E.M., Polman C.H.: Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist. Mult. Scler. 10: 330-331 (2004)

18. Croxford J.L., Miller S.D.: Towards cannabis and can­nabinoid treatment of multiple sclerosis. Drugs Today 40: 663-676 (2004)

19. Pertwee R.G.: Cannabinoids and multiple sclerosis. Phar­macol. Ther. 95: 165-174 (2002)

20. Svendsen K.B., Jensen T.S., Bach F.W.: Does the can­nabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 329: 253 (2004)

21. Killestein J., Uitdehaag B.M., Polman C.H.: Cannabi­noids in multiple sclerosis: do they have a therapeutic role. Drugs 64: 1-11 (2004)

22. Zajicek J., Fox P., Sanders H., Wright D., Vickery J., Nunn A., Thompson A.: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362: 1517-1526 (2003)

23. Schwenkreis P., Tegenthoff M.: [Therapeutic use of can­nabinoids in neurology]. Schmerz 17: 367-373 (2003)

24. Baker D., Pryce G.: The therapeutic potential of can­nabis in multiple sclerosis. Expert Opin. Investig. Drugs 12: 561-567 (2003)

25. Grundy R.I.: The therapeutic potential of the cannabi­noids in neuroprotection. Expert Opin. Investig. Drugs 11: 1365-1374 (2002)

26. Smith P.F.: Cannabinoids in the treatment of pain and spasticity in multiple sclerosis. Curr. Opin. Investig. Drugs 3: 859-864 (2002)

27. Szendrei K.: [A novel analgesics made from Canna­bis]. Ideggyogy Sz. 57: 36-40 (2004)

28. http://www.pharma.bayer.com/en/aboutbayerpharma/ news_room/article/1060723499797/1060008228455/21.html

29. Holdcroft A., Smith M., Jacklin A., Hodgson H., Smith B., Newton M., Evans F.: Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 52: 483-486 (1997)

30. Wood S.: Evidence for using cannabis and cannabi­noids to manage pain. Nurs. Times 100: 38-40 (2004)

31. Rice A.S.: Cannabinoids and pain. Curr. Opin. Investig. Drugs 2: 399-414 (2001)

32. Walker J.M., Strangman N.M., Huang S.M.: Cannabi­noids and pain. Pain Res. Manag. 6: 74-79 (2001)

33. Buggy D.J., Toogood L., Maric S., Sharpe P., Lambert D.G., Rowbotham D.J.: Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain 106: 169-172 (2003)

34. http://www.idmu.co.uk/cannmigraine.htm

35. http://www.druglibrary.net/olsen/HEMP/IHA/iha01104. html

36. Mechoulam R., Panikashvili D., Shohami E.: Cannabi­noids and brain injury: therapeutic implications. Trends Mol. Med. 8: 58-61 (2002)

37. http://www.idmu.co.uk/canncardio.htm

38. Croxford J.L.: Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 17: 179-202 (2003)

39. Drysdale A.J., Platt B.: Cannabinoids: mechanisms and therapeutic applications in the CNS. Curr. Med. Chem. 10: 2719-2732 (2003)

40. Martin B.R., Wiley J.L.: Mechanism of action of can­nabi­noids: how it may lead to treatment of cachexia, eme­sis, and pain. J. Support. Oncol. 2: 305-316 (2004).

41. Grotenhermen F., Muller-Vahl K.: IACM 2nd Confer­ence on Cannabinoids in Medicine. Expert. Opin. Pharma­cother. 4: 2367-2371 (2003)

42. Hall W., Christie M., Currow D.: Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol. 6: 35-42 (2005)

43. Guzman M.: Cannabinoids: potential anticancer agents. Nat. Rev. Cancer 3: 745-755 (2003)

44. Coutts A.A., Izzo A.A.: The gastrointestinal pharmacol­ogy of cannabinoids: an update. Curr. Opin. Pharmacol. 4: 572-579 (2004)

45. Carter G.T., Ugalde V.: Medical marijuana: emerging appli­cations for the management of neurologic disorders. Phys. Med. Rehabil. Clin. N. Am. 15: 943-954 (2004)

46. Blazquez C., Casanova M.L., Planas A., Del Pulgar T.G., Villanueva C., Fernandez-Acenero M.J., Aragones J., Huffman J.W., Jorcano J.L., Guzman M.: Inhibition of tumor angiogene­sis by cannabinoids. FASEB J. 17: 529-531 (2003)

47. Adami M., Zamfirova R., Sotirov E., Tashev R., Dobri­nova Y., Todorov S., Coruzzi G.: Gastric antisecretory effects of synthetic cannabinoids after central or peripheral administra­tion in the rat. Brain Res. Bull. 64: 357-361 (2004)

48. Izzo A.A., Mascolo N., Capasso F.: Forgotten target for marijuana:the endocannabinoid system in the gut. TiPS 21: 372 (2000)

49. Izzo A.A., Fezza F., Capasso R., Bisogno T., Pinto L., Iu­vone T., Esposito G., Mascolo N., Di Marzo V., Capasso F.: Cannabinoid CB1-receptor mediated regulation of gastrointes­tinal motility in mice in a model of intestinal inflammation. Br. J. Pharmacol. 134: 563-570 (2001)

50. Klein T.W., Newton C.A., Friedman H.: Cannabinoids and the immune system. Pain Res. Manag. 6: 95-101 (2001)

51. Walter L., Stella N.: Cannabinoids and neuroinflamma­tion. Br. J. Pharmacol. 141: 775-785 (2004)

52. http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1. monographs/CPS-%20Monographs/CPS-%20(General% 20Monographs-%20C)/CESAMET.html

53. http://pharmacy.oregonstate.edu/drug_policy/reviews-evaluations/dronabinol.html

54. http://www.solvaypharma.ca/en/areas/appetite4.asp

55. Martin B., Sim-Selley L., Selley D.: Signaling pathways involved in the development of cannabinoid tolerance, TiPS 25:325-330 (2004)

56. Naef M., Curatolo M., Petersen-Felix S., Arendt-Niel­sen L., Zbinden A., Brenneisen R.: The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain con­ditions. Pain 105: 79-88 (2003)

57. http://health.in.gr/news/article.asp?lngArticleID=42075

58. The United Nations and Drug Control, Division of Nar­cotic Drugs-Vienna, Cannabis, pp. 11-13, United Nations, N.Y, 1982